Metadon Pharmadone 80 mg Oral lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

metadon pharmadone 80 mg oral lösning

unimedic pharma ab - metadonhydroklorid - oral lösning - 80 mg - metadonhydroklorid 80 mg aktiv substans; glukosmonohydrat hjälpämne; sackaros hjälpämne; metylparahydroxibensoat hjälpämne - metadon

Metadon Pharmadone 90 mg Oral lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

metadon pharmadone 90 mg oral lösning

unimedic pharma ab - metadonhydroklorid - oral lösning - 90 mg - metadonhydroklorid 90 mg aktiv substans; glukosmonohydrat hjälpämne; sackaros hjälpämne; metylparahydroxibensoat hjälpämne - metadon

Paracetamol Panpharma 10 mg/ml Infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paracetamol panpharma 10 mg/ml infusionsvätska, lösning

panpharma sa - paracetamol - infusionsvätska, lösning - 10 mg/ml - glukosmonohydrat hjälpämne; paracetamol 10 mg aktiv substans - paracetamol

Gentamicin Panpharma 40 mg/ml Injektions-/infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

gentamicin panpharma 40 mg/ml injektions-/infusionsvätska, lösning

panpharma sa - gentamicinsulfat - injektions-/infusionsvätska, lösning - 40 mg/ml - gentamicinsulfat 67,8 mg aktiv substans

Dexamfetamin Sea Pharma 5 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dexamfetamin sea pharma 5 mg tablett

sea pharma ab - dexamfetaminsulfat - tablett - 5 mg - dexamfetaminsulfat 5 mg aktiv substans; isomalt hjälpämne

Dexamfetamin Sea Pharma 10 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dexamfetamin sea pharma 10 mg tablett

sea pharma ab - dexamfetaminsulfat - tablett - 10 mg - isomalt hjälpämne; dexamfetaminsulfat 10 mg aktiv substans

Dexamfetamin Sea Pharma 20 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dexamfetamin sea pharma 20 mg tablett

sea pharma ab - dexamfetaminsulfat - tablett - 20 mg - isomalt hjälpämne; dexamfetaminsulfat 20 mg aktiv substans

Midazolam Panpharma 1 mg/ml Injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

midazolam panpharma 1 mg/ml injektionsvätska, lösning

panpharma sa - midazolam - injektionsvätska, lösning - 1 mg/ml - midazolam 1 mg aktiv substans - midazolam

Midazolam Panpharma 5 mg/ml Injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

midazolam panpharma 5 mg/ml injektionsvätska, lösning

panpharma sa - midazolam - injektionsvätska, lösning - 5 mg/ml - midazolam 5 mg aktiv substans - midazolam

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Europeiska unionen - svenska - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.